Dive into the archives.
- Novartis says FTY720 reduces relapses
ZURICH, Sept 30 (Reuters) – Swiss drugmaker Novartis AG said on Wednesday its FTY720 oral drug to treat multiple sclerosis reduced both relapses and disability progression.
Initial results from the two-year Phase III study show that oral FTY720 was significantly superior to placebo in reducing both relapses and disability progression in patients with relapsing-remitting multiple sclerosis, [...]
- Hot off the ECTRIMS Press…Sanofi Oral is Promising
LONDON, Sept 11 (Reuters) – Patients given an experimental multiple sclerosis tablet from Sanofi-Aventis showed a significant improvement compared to those on placebo in a mid-stage test, researchers said on Friday.
Teriflunomide, which was used as an add-on therapy to interferon beta in the Phase II clinical trial, is one of a number of MS drugs [...]
- Hot off the ECTRIMS Press…Cladribine Reduces Disease Activity in a Big Way
Darmstadt, Germany, September 11, 2009 – Merck KGaA announced today new data from a post-hoc analysis of the two-year (96-week) placebo-controlled CLARITY(1) Phase III trial using a short-course of Cladribine Tablets (the proprietary investigational oral formulation of cladribine) to treat patients with relapsing-remitting multiple sclerosis (MS). The data from this post-hoc analysis of the CLARITY [...]
- Merck Sumbits Cladribine Application for EU Approval
July 23, 2009 — 9:05am ET | By John Carroll
Racing to beat Novartis to the world’s biggest drug markets with a new oral therapy for multiple sclerosis, Merck KGaA has filed for regulatory approval of cladribine in Europe and plans to file in the U.S. later this quarter.
The application brings Merck ”closer to the possibility of providing an [...]
- Teva completes enrollment in second Phase III trial
Jun 26, 2009 (Datamonitor via COMTEX) — Teva Pharmaceutical Industries, an Israeli generic pharmaceutical company, and Active Biotech, a Swedish pharmaceutical company, have completed patient enrollment for the second pivotal Phase III clinical trial, Bravo, evaluating the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis.
// Bravo is a global clinical [...]
- Hot off the ENS Press: Cladribine Is Safe Overall in Patients With Multiple Sclerosis
MILAN, Italy — June 24, 2009 — According to a safety analysis of a study presented here at the 19th Meeting of the European Neurological Society (ENS), the incidence of treatment-emergent adverse events in the trial was comparable between 2 doses of cladribine and placebo in patients with multiple sclerosis (MS), with exceptions related to [...]
- Hot off the AAN Press: Laquinimod, New Data, Novel MOA
New Data Illustrate Novel Mechanism OF Action of Laquinimod, an Oral Compound for the Treatment of Multiple Sclerosis
-Researchers Demonstrate Immunomodulatory Effects of Laquinimod on Disease Activity
Jerusalem, Israel, Lund, Sweden and Seattle, Washington, April 28, 2009 – Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from several new [...]
- Hot off the AAN Press: Fingolimod effective but safety an issue
UPDATE 3-Novartis MS drug effective but safety an issue
ZURICH, April 29 (Reuters) – Novartis AG said 80-83 percent of those taking its multiple sclerosis drug FTY720 are relapse-free compared with 69 percent on the leading current treatment, but it reported a new patient death.
Novartis said the patient died from aspiration pneumonia related to a [...]
- Novartis MS drug linked to new side effect
LONDON, April 14 — Fresh side-effect problems have emerged with Novartis AG’s experimental oral multiple sclerosis (MS) drug FTY720, with doctors reporting a case of haemorrhaging focal encephalitis.
A case report on the patient who developed the condition after taking part in a Phase III clinical trial of the medicine — one of the big hopes [...]
- 11 MS Drugs May Soon Be on Pharmacy Shelves (or Infusion Suites) Near YOU
Several New MS Drugs Could Soon Be On the Market
(Ivanhoe Newswire) — Patients with multiple sclerosis (MS) may soon have more treatment options for their disease.
A new report in Chemical & Engineering News says years of scientific research on MS means 11 potential new drugs are now in the final stages of clinical trials and [...]
